Latest Breaking News On - நிறுவனம் நெதர்லாந்து - Page 7 : comparemela.com
Les Pays-Bas : l un des gagnants du Brexit ?
contrepoints.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from contrepoints.org Daily Mail and Mail on Sunday newspapers.
Jacques-Olivier Martin: «Le temps des tulipes»
lefigaro.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lefigaro.fr Daily Mail and Mail on Sunday newspapers.
Taïwan, un long chemin vers la démocratie - La marche du monde
rfi.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rfi.fr Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model
February 17, 2021 GMT
LONDON (BUSINESS WIRE) Feb 17, 2021
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces the world’s first COVID-19 characterization study has received approval from a specially convened Research Ethics Committee (REC). This news follows the announcement on October 20, 2020 of Open Orphan subsidiary hVIVO’s contract with the UK Government to develop a COVID-19 human challenge study model.
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world s first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.